



22nd February 2022

Xagrid (anagrelide hydrochloride): Risk of thrombosis including cerebral infarction upon abrupt treatment discontinuation

Ref: EMEA/H/C/000480

Dear Healthcare Professional,

Takeda Pharmaceuticals International AG Ireland Branch in agreement with the European Medicines Agency (EMA) and Health Products Regulatory Authority (HPRA) would like to inform you of the following:

Summary

- **There is an increased risk of thrombotic complications, including cerebral infarction, upon abrupt anagrelide discontinuation.**
- **Abrupt treatment discontinuation should be avoided due to the risk of sudden increase in platelet counts and potentially fatal thrombotic complications, such as cerebral infarction.**
- **In the event of dosage interruption or treatment withdrawal, monitor platelet counts frequently (refer to SmPC Section 4.4).**
- **Advise patients how to recognize early signs and symptoms suggestive of thrombotic complications, such as cerebral infarction, and if symptoms occur to seek medical assistance.**

Background on the safety concern

Xagrid (anagrelide) is indicated for the reduction of elevated platelet counts in at risk patients with essential thrombocythemia who are intolerant to their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy.

A cumulative analysis of company safety database till 6 August 2021 showed 15 events of thrombotic complications, including cerebral infarction, after a recent discontinuation of anagrelide. It was concluded that cerebral infarction, along with other thrombotic complications, while being part of the pre-existing condition/indication, may also occur upon abrupt anagrelide discontinuation, inadequate dosing, or lack of effect.

The mechanism of cerebral infarction following abrupt treatment discontinuation is related to the rebound in platelet count. Platelet count typically will start to rise within 4 days after discontinuation and return to baseline levels in one to two weeks, possibly rebounding above baseline values.

Takeda Products Ireland Limited

Trading address: 5 Riverwalk, Citywest Business Campus, Dublin 24, Ireland
 Registered office: 6th Floor, South Bank House, Barrow Street, Dublin 4, Ireland
 Tel: +353 (1) 642 0021
www.takeda.com/en-ie
 Registered in Ireland No. 443657
 Directors: S. O'Reilly, D. A. Ahern, J. Ryan



Based upon the available information, the safety information under Section 4.4 "Special Warnings and Precautions for Use" and section 4.8 "Undesirable Effects of Summary of Product Characteristics (SmPC)" will be updated to reflect the latest data and recommendations.

Call for reporting

Please report any adverse events experienced by your patients taking Xagrid (anagrelide). Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. When reporting, please provide as much information as possible including information about batch details, medical history, any concomitant medication, onset and treatment dates.

Healthcare professionals are asked to report any suspected adverse reactions via HPRC Pharmacovigilance, website: www.hpra.ie.

Healthcare professionals can also report any suspected adverse reactions associated with the use of Xagrid to Takeda Products Ireland Ltd via: AE.GBR-IRL@takeda.com.

Should you have any questions or require further information regarding Xagrid, please contact Takeda using the contact details below.

Company contact point(s)

Dr Simon Meadowcroft
Medical Director UK & Ireland
Mobile: +44 (0)7766 526793
Address: 1 Kingdom Street
London W2 6BD

Takeda Products Ireland Ltd. Medical Information
e-mail: medinfoemea@takeda.com
Med Info. direct line: 1800 937 970 (freephone from Ireland only) or +44 (0) 3333 000 181
Drug safety e-mail: AE.GBR-IRL@Takeda.com

Should you have any queries regarding this notification, please contact us using the details provided above.

Yours sincerely,

Dr Simon Meadowcroft
Medical Director UK & Ireland
Takeda UK
BSc MBChB (hons) MRCGP MFPM

Takeda Products Ireland Limited

Trading address: 5 Riverwalk, Citywest Business Campus, Dublin 24, Ireland
Registered office: 6th Floor, South Bank House, Barrow Street, Dublin 4, Ireland
Tel: +353 (1) 642 0021
www.takeda.com/en-ie
Registered in Ireland No. 443657
Directors: S. O'Reilly, D. A. Ahern, J. Ryan